Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures Connect Biopharma NASDAQ: CNTB rep...
Topics
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met its primary objective, showing reductions in treatment failures during the month after an exacerbation.
Related QATS news
- Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Novo Nordisk is a leading GLP-1 company, ...
- Kodiak AI Targets Year-End Driverless Dallas-Houston Trucking Launch With IKEA Kodiak AI NASDAQ: KD...
- Forget the S&P 500: SCHD Is Beating It by Nearly 10 Points in 2026 and Its Dividend Just Grew SCHD ...
- Is Netflix (NFLX) Stock a Buy? Netflix is huge and still growing. But its valuation isn't dirt chea...